Sodium Bicarbonate in Intra-dialytic Hypertension in Chronic Hemodialysis Patients
Not Applicable
Not yet recruiting
- Conditions
- Hypertension in Dialysis Patients
- Interventions
- Drug: Sodium Bicarbonate (NaHCO3)Drug: Placebo
- Registration Number
- NCT07231900
- Lead Sponsor
- Assaf-Harofeh Medical Center
- Brief Summary
The study is designed to diminish intra-dialytic hypertension in chrnic hemodialysis patients suffering from metabolic acidosis (low bicarbonate levels). The intervention is a tab of 500 mg sodium bicarbonate twice a day for one month, vs. placebo.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
- Chronic hemodialysis patient > 3 months
- 3 dialysis per week, KTV>1.2
- capable of informed concent.
- rise in blood pressure during hemodialysis > 10 mm Hg, for at least 50% of dialysis sessions in the month prior to inclusion.
- Normal volume status, by clinical physician assessment + bioimpedance
Exclusion Criteria
- age under 18,
- pregnancy
- unable to sign informed concent
- planned for kidney transplant in the following 3 month.
- congestive heart failure (NYHA 3-4)
- hospitalization for acute MI or CHF in the past 3 months.
- low compliece to medical therapy
- regular pre-dialysis tests with bicarbonate > 24 in the past 3 months
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Sodium bicarbonate Sodium Bicarbonate (NaHCO3) PO Sodium bicarbonate 500mg X2/day Placebo Placebo 1 tab X2/day
- Primary Outcome Measures
Name Time Method Blood pressure 1 month Prevention of intra dialytic hypertension
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Shamir medical center
🇮🇱Ẕerifin, Is, Israel
Shamir medical center🇮🇱Ẕerifin, Is, Israel